acetaminophen / NO Cancer Research Results

acet, acetaminophen: Click to Expand ⟱
Features:

Acetaminophen — Acetaminophen (also called paracetamol; common abbreviation APAP) is a small-molecule analgesic and antipyretic used for pain and fever. It is a non-opioid, non-NSAID analgesic with weak peripheral anti-inflammatory activity compared with NSAIDs, and its clinically relevant actions are largely central (CNS) rather than peripheral. It is widely available OTC and in many combination products; overdose risk is driven by total aggregate APAP exposure across products.

Primary mechanisms (ranked):

  1. Central prostaglandin synthesis suppression via inhibition of prostaglandin H synthase (COX peroxidase site) under low-peroxide conditions → ↓PGE2 signaling (analgesic/antipyretic dominant)
  2. Central neuromodulation (context-dependent): serotonergic descending inhibitory pathways and endocannabinoid-related signaling (including AM404 formation) contributing to analgesia
  3. Thermoregulatory set-point effects in hypothalamus downstream of ↓PGE2 (antipyresis)
  4. High-dose/toxicity mechanism: CYP-mediated bioactivation → NAPQI formation → glutathione depletion, mitochondrial oxidative stress and hepatocellular injury

Bioavailability / PK relevance: Oral acetaminophen is generally well absorbed; therapeutic plasma half-life is typically ~1.5–3 hours in adults, with hepatic clearance dominated by glucuronidation and sulfation; a smaller fraction undergoes CYP oxidation to NAPQI. Hepatotoxic risk increases when detox capacity (glutathione) is compromised or when oxidative bioactivation is increased.

In-vitro vs systemic exposure relevance: Therapeutic effects are not typically driven by high cytotoxic concentrations; many cell-culture toxicity phenotypes reflect supratherapeutic exposure and/or bioactivation contexts not representative of normal systemic dosing.

Clinical evidence status: Established standard-of-care symptomatic therapy (OTC and prescription formulations) for pain and fever; major safety signal is dose-dependent hepatotoxicity from overdose and unintentional “stacking” across combination products.


Pathways:
-Cytochrome P450 Metabolism: NAPQI (N-acetyl-p-benzoquinone imine)
-Excess NAPQI depletes glutathione, a key antioxidant. The absence of sufficient glutathione leads to elevated oxidative stress.
-NF-κB Activation:
-Direct DNA Damage:

Excess results in increased oxidative stress, mitochondrial dysfunction, and ultimately hepatocellular damage (liver injury)

Mechanistic axes relevant to acetaminophen (therapeutic action and dose-limiting toxicity)

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Central prostaglandin synthesis ↔ (not a primary anticancer mechanism) ↓ PGE2 signaling in CNS P–R Analgesia, antipyresis Clinically consistent with central COX/PGHS functional inhibition (peroxidase-site, redox-state dependent) with minimal peripheral anti-inflammatory effect vs NSAIDs.
2 Serotonergic descending pain inhibition ↔ ↑ descending inhibitory tone (context-dependent) P–R Analgesia Frequently described as contributory; magnitude varies by model and co-administered agents.
3 Endocannabinoid-related signaling and TRPV1 (AM404 axis) ↔ ↑ cannabinoid/TRPV1-linked modulation (context-dependent) R Analgesia (adjunctive) AM404 is a CNS metabolite implicated in some mechanistic models; relevance varies across species and experimental systems.
4 ROS and mitochondrial oxidative stress (toxicity axis) ↑ (high concentration only) ↑ (overdose context) R–G Hepatocellular injury Overdose: NAPQI formation + GSH depletion → mitochondrial dysfunction and oxidative stress; this is dose-limiting and not a therapeutic mechanism.
5 NRF2 and glutathione homeostasis (toxicity modifier) ↔ (context-dependent) ↑ adaptive response; ↓ GSH predisposes to injury G Determines resilience to NAPQI Risk is increased when baseline GSH is low (e.g., fasting/starvation) or when metabolism shifts toward oxidation pathways.
6 Clinical Translation Constraint — — — Dose ceiling due to hepatotoxicity risk Major real-world risk is inadvertent overdose from multi-product use; labeling emphasizes total daily maximum across all sources/routes.


NO, Nitric Oxide: Click to Expand ⟱
Source:
Type:
Once the cancer has begun, NO seems to play a protumoral role rather than antitumoral one as the concentration required to cause tumor cell cytotoxicity cannot be achieved by cancer cells.
The mechanistic roles of nitric oxide (NO) during cancer progression have been important considerations since its discovery as an endogenously generated free radical. Nonetheless, the impacts of this signaling molecule can be seemingly contradictory, being both pro-and antitumorigenic, which complicates the development of cancer treatments based on the modulation of NO fluxes in tumors. At a fundamental level, low levels of NO drive oncogenic pathways, immunosuppression, metastasis, and angiogenesis, while higher levels lead to apoptosis and reduced hypoxia and also sensitize tumors to conventional therapies. However, clinical outcome depends on the type and stage of the tumor as well as the tumor microenvironment.
Nitric oxide is generated by three main nitric oxide synthase isoforms: neuronal (nNOS), endothelial (eNOS), and inducible (iNOS).

– In many cancers, especially under inflammatory conditions, iNOS expression is upregulated. In contrast, eNOS levels may also be altered in cancers such as breast or prostate cancer.

• Expression Patterns in Tumors:
– Elevated iNOS expression is commonly observed in various tumor types (e.g., colon, breast, lung, and melanoma) and is often associated with an inflammatory microenvironment.

– Changes in eNOS and nNOS expression have also been reported and may contribute to angiogenesis and tumor blood flow regulation.
Scientific Papers found: Click to Expand⟱
1478- SFN,  acet,    Anti-inflammatory and anti-oxidant effects of combination between sulforaphane and acetaminophen in LPS-stimulated RAW 264.7 macrophage cells
- in-vitro, Nor, NA
eff↑, NO↓, iNOS↓, COX2↓, IL1β↓, ROS↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

ROS↓, 1,  

Cell Death ⓘ

iNOS↓, 1,  

Angiogenesis & Vasculature ⓘ

NO↓, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 1,   IL1β↓, 1,  

Drug Metabolism & Resistance ⓘ

eff↑, 1,  
Total Targets: 6

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: NO, Nitric Oxide
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:275  Target#:563  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page